BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...are in the clinic for treatment-resistant hypertension, with the most advanced being Phase III compound aprocitentan...
BioCentury | Dec 8, 2017
Company News

J&J opts in for Idorsia's hypertension candidate

...Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577...
...and its derivatives. Idorsia will be responsible for Phase III development and regulatory submission of aprocitentan...
...pipeline businesses (see BioCentury, Feb. 3 & BioCentury, May 26 ). In May, Actelion said aprocitentan...
BioCentury | Dec 4, 2017
Company News

J&J opts in for Idorsia's hypertension candidate

...Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577...
...and its derivatives. Idorsia will be responsible for Phase III development and regulatory submission of aprocitentan...
...pipeline businesses (see BioCentury, Feb. 3 & BioCentury, May 26) . In May, Actelion said aprocitentan...
BioCentury | Jun 16, 2017
Financial News

Actelion spinout Idorsia rises in first trading day

...Extra, June 9) . Idorsia’s pipeline includes several candidates in Phase II testing, including aprocitentan (ACT-132577...
BioCentury | Jun 9, 2017
Financial News

Actelion spinout Idorsia to list next week

...May 26) . Idorsia’s pipeline will include several candidates in Phase II, including aprocitentan ( ACT-132577...
BioCentury | May 26, 2017
Clinical News

Actelion's endothelin receptor antagonist reduces blood pressure in Phase II

...Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "significant dose-dependent" reductions in diastolic and systolic blood pressure...
...patients in the per protocol (PP) population, once-daily 5, 10, 25 and 50 mg oral ACT-132577...
...ACT-132577 is an orally active dual endothelin receptor antagonist. Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Product: ACT-132577...
BioCentury | May 22, 2017
Clinical News

Actelion reports hypertension data amid Idorsia spinout

...candidates it plans to spin out into newco Idorsia Ltd. , Actelion Ltd. (SIX:ATLN) said ACT-132577...
...Among 410 patients in the Phase II trial's per protocol population, four doses of ACT-132577...
...in an arm of patients receiving lisinopril. Also from baseline to week eight, the four ACT-132577...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

...Phase II readouts only a few months after starting.” Data will come this half from ACT-132577...
...including five Phase II programs expecting data this year. (A) J&J has an option to ACT-132577...
BioCentury | Jan 27, 2017
Company News

J&J acquiring Actelion, spinning out newco

...come from J&J's "equity engagement." J&J will also hold an option to obtain rights to ACT-132577...
BioCentury | Jan 27, 2017
Company News

J&J, Actelion deal

...come from J&J's "equity engagement." J&J will also hold an option to obtain rights to ACT-132577...
Items per page:
1 - 10 of 10